Neuroleptic malignant syndrome is a rare, life-threatening idiosyncratic reaction to dopamine-blocking agents characterized by the classic tetrad of fever, muscular rigidity, dysautonomia, and altered mental status. Incidence is estimated at 0.01–0.02% of patients treated with antipsychotics, with most cases occurring within the first 30 days of therapy and a median onset of 4 days after drug exposure. [1-2]
1. History
- Medication exposure is the single most critical HPI element: Which dopamine-blocking agent? When started, dose changed, or route changed? Any recent IM/depot injection?
- Onset typically hours to days after initiation, dose increase, or switch of a neuroleptic; median 4 days, virtually all within 30 days [1-2]
- Symptom progression: mental status changes and blood pressure alterations often appear first, followed by rigidity and fever peaking on day 2–3 [1-2]
- Ask about dysphagia, difficulty speaking/mutism, tremor, diaphoresis, urinary incontinence [1-2]
- Inquire about recent dehydration, exhaustion, agitation, physical restraint use, ambient heat exposure
- Important negatives: recent anesthesia (malignant hyperthermia), serotonergic drug use (serotonin syndrome), abrupt discontinuation of dopaminergic agents or baclofen [1-2]
2. Alarm Features
- Temperature ≥40°C (104°F) — reflects breakdown of central thermoregulation [1-2]
- Severe "lead-pipe" rigidity unresponsive to antiparkinsonian agents — risk of rhabdomyolysis and renal failure [1]
- Acute respiratory distress from rigidity of upper-airway muscles, respiratory musculature, and diaphragm — may require emergent intubation [1]
- Rapidly fluctuating blood pressure with hemodynamic instability [1-2]
- CK >10,000 U/L — high risk of acute kidney injury [1]
- Stupor or coma — indicates severe catatonic state [2]
- Aspiration from ineffective cough and sialorrhea [1]
3. Medications
Causative agents
- First-generation antipsychotics (highest risk): haloperidol, chlorpromazine, fluphenazine [1][3]
- Second-generation antipsychotics: olanzapine, risperidone, quetiapine, aripiprazole, clozapine — lower risk but still implicated; rigidity may be less prominent [1]
- Non-psychiatric dopamine blockers: metoclopramide, prochlorperazine, promethazine, droperidol [2]
- Long-acting injectables (paliperidone palmitate, fluphenazine decanoate) — prolonged course due to slow drug clearance, up to 60 days to undetectable levels [1][4]
Treatments
- Dantrolene — direct skeletal muscle relaxant (inhibits sarcoplasmic reticulum calcium release); monitor for hepatotoxicity [1]
- Bromocriptine — dopamine agonist; displaces antipsychotic at D2 receptor [1]
- Amantadine — alternative dopamine agonist [1]
- Lorazepam — for mild rigidity and agitation [1]
- Dexmedetomidine — for sedation/agitation management to avoid reintroducing antipsychotics [1]
Contraindicated/avoid
- Do NOT reintroduce antipsychotics or other dopamine blockers during the acute episode [1]
- Withhold lithium, anticholinergics, and serotonergic agents if possible to avoid confounding the clinical picture [1]
4. Diet
- Aggressive IV hydration is the priority — patients are typically severely dehydrated from fever, diaphoresis, and rigidity [1]
- NPO if altered mental status, dysphagia, or aspiration risk
- No specific dietary triggers; however, dehydration and poor oral intake are recognized risk factors for developing NMS [2]
5. Review of Systems
- Neuro: altered consciousness, mutism, tremor, dysphagia, dysarthria, incontinence
- MSK: generalized rigidity, muscle pain/tenderness (rhabdomyolysis)
- Autonomic: diaphoresis, palpitations, urinary incontinence, pallor
- Respiratory: dyspnea, ineffective cough, sialorrhea
- GI: dysphagia, decreased oral intake
- Renal: decreased urine output, dark urine (myoglobinuria)
- Cardiac: chest pain (demand ischemia in patients with CAD) [1]
6. Collateral History and Family History
- Prior NMS episode — recurrence reported in 15–20% of index cases; this is the strongest individual risk factor [2]
- Psychiatric diagnosis and medication history from caregivers, pharmacy records, or outpatient psychiatrist
- Recent medication changes, adherence issues, or depot injection dates
- Genetic susceptibility: DRD2 A1 allele overrepresentation reported; CYP2D6 poor metabolizer status has been studied but does not clearly confer increased risk [1]
- Family history of NMS or malignant hyperthermia (shared pathophysiologic features)
7. Risk Factors
- Pharmacologic: high-potency antipsychotics, rapid dose escalation, IM/parenteral route, polypharmacy with multiple antipsychotics, high total dose [1-2][5]
- Clinical: dehydration, agitation, exhaustion, catatonia, disorganized behavior, iron deficiency [2][5]
- Patient factors: prior NMS episode, anti-NMDAR encephalitis (47% "neuroleptic intolerance" in one study), male sex (more commonly reported) [1][6]
- Contextual: postoperative setting with antipsychotic use for delirium/agitation (20% of cases in one series) [7]
8. Differential Diagnosis
- Serotonin syndrome — hyperreflexia, clonus, myoclonus, shivering (vs. lead-pipe rigidity and diminished/normal reflexes in NMS); serotonergic drug exposure [1]
- Malignant hyperthermia — occurs during/after anesthesia with volatile agents or succinylcholine; similar rigidity and hyperthermia but different context [1]
- Malignant (lethal) catatonia — may be indistinguishable; some experts consider NMS a drug-induced form; look for stereotypy, cataplexy, mannerisms [1][8]
- Parkinsonism-hyperpyrexia syndrome — abrupt withdrawal of dopaminergic medications in Parkinson's disease [9]
- Heat stroke — environmental exposure, anhidrosis, no rigidity
- CNS infection (meningitis/encephalitis) — fever + AMS but no rigidity; CSF abnormalities
- Anti-NMDAR encephalitis — can mimic NMS and worsen with antipsychotics; consider in young women with psychiatric symptoms [1][8]
- Sympathomimetic toxicity (cocaine, amphetamines, MDMA) — agitation, hyperthermia, but different drug exposure [1]
- Baclofen withdrawal — rigidity and mental status changes after abrupt discontinuation [1]
- Thyrotoxicosis, pheochromocytoma, tetanus, status epilepticus [2]
Key distinguishing pearl: NMS has lead-pipe rigidity with normal or diminished reflexes; serotonin syndrome has hyperreflexia and clonus. [1]
9. Past Medical History
- Prior NMS episode — most important historical factor
- Psychiatric diagnoses: schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder (most common underlying conditions) [7]
- History of catatonia or extrapyramidal side effects with antipsychotics
- Chronic medical conditions: CAD (risk of demand ischemia), CKD (impaired drug clearance, higher rhabdomyolysis risk)
- Surgical history: recent surgery with postoperative antipsychotic use [7]
10. Physical Exam
Vital signs
- Hyperthermia: >38°C, often ≥40°C [1-2]
- Tachycardia: ≥25% above baseline [2][10]
- Blood pressure: labile — hypertensive or hypotensive, fluctuating ≥20 mmHg diastolic or ≥25 mmHg systolic within 24 hours [2][10]
- Tachypnea: ≥50% above baseline [2]
Focused exam
- Neuro: "Lead-pipe" rigidity — uniform resistance throughout passive ROM; cogwheeling may be superimposed; tremor; mutism; stupor or catatonia; diminished or normal deep tendon reflexes [1]
- Skin: profuse diaphoresis, pallor
- Oropharyngeal: sialorrhea, trismus, dysphagia
- Respiratory: chest wall rigidity, decreased breath sounds (aspiration), ineffective cough
- Abdomen: incontinence
- Extremities: compartment syndrome (rare, from severe localized rhabdomyolysis) [1]
11. Lab Studies
Recommended initial labs
- CK (creatine kinase) — often markedly elevated; ≥4× ULN supports diagnosis; can reach >10,000 U/L [1-2][10]
- BMP — hyperkalemia, hypocalcemia, hypernatremia/hyponatremia, elevated creatinine (AKI from rhabdomyolysis) [1]
- CBC — leukocytosis (common, nonspecific) [1]
- LFTs — elevated LDH, alkaline phosphatase, aminotransferases (common but transient) [1]
- Lactate — metabolic acidosis
- ABG/VBG — acidosis, hypoxia
- Urinalysis — myoglobinuria
- Serum iron — decreased (may support diagnosis) [2]
- Troponin — demand ischemia, especially in patients with CAD [1]
- Coagulation studies — DIC screening in severe cases
Important caveats
- CK may be normal early in the course and give false reassurance [1]
- No single lab abnormality is diagnostic [2]
- CSF and neuroimaging are generally normal — useful to rule out CNS infection [2]
12. Imaging
- Imaging is primarily used to exclude alternative diagnoses, not to confirm NMS
- CT head — rule out structural CNS pathology if altered mental status
- Chest X-ray — evaluate for aspiration pneumonia, pulmonary edema
- MRI brain — generally normal in NMS; consider if concern for encephalitis or structural lesion [2]
- Neuroimaging findings are nonspecific in NMS [2]
13. Special Tests
- EEG — generalized slowing (nonspecific); useful to rule out nonconvulsive status epilepticus [2]
- Lumbar puncture — CSF generally normal; perform if CNS infection is on the differential [2]
- Delphi consensus diagnostic criteria: [10]
- Recent dopamine antagonist exposure (or dopamine agonist withdrawal)
- Hyperthermia (>38.0°C on ≥2 occasions)
- Rigidity
- Mental status alteration
- CK elevation (≥4× ULN)
- Sympathetic nervous system lability
- Tachycardia + tachypnea
- Negative workup for other causes
- DSM-5 criteria: dopamine-blocking drug exposure + severe rigidity + fever + ≥2 of: diaphoresis, dysphagia, tremor, incontinence, altered consciousness, mutism, tachycardia, labile BP, leukocytosis, elevated CK [1]
14. ECG
- Sinus tachycardia — most common finding
- Tachyarrhythmias — may occur with severe dysautonomia [3]
- Obtain ECG to evaluate for demand ischemia (ST changes, T-wave inversions) in patients with CAD or elevated troponin [1]
- Rule out QTc prolongation — many causative antipsychotics prolong QTc independently
- Monitor for hyperkalemia-related changes (peaked T waves, widened QRS) from rhabdomyolysis
15. Assessment
- NMS is a clinical diagnosis based on the constellation of dopamine-blocker exposure + fever + rigidity + dysautonomia + altered mental status [1]
- Severity ranges from mild (low-grade fever, mild rigidity, cogwheeling) to fulminant (temperature >41°C, severe rigidity, respiratory failure, rhabdomyolysis with AKI) [1]
- Atypical presentations are increasingly recognized with second-generation antipsychotics — rigidity may be less prominent [1][4]
- NMS is frequently overdiagnosed — in one Mayo Clinic series, only 20 of 332 coded cases (6%) met strict DSM-5 criteria [7]
- Complications: rhabdomyolysis (up to 30%), AKI, aspiration pneumonia, respiratory failure, DIC, cardiac arrest, sepsis [1]
- Historical mortality 20–30%; contemporary mortality approximately 5–15% with improved recognition and ICU care [1]
16. Treatment Plan
Immediate stabilization
- Stop the offending agent immediately — this is the single most important intervention [1][8]
- ABCs — intubate if respiratory distress from chest wall rigidity, aspiration, or airway compromise [1]
- Aggressive IV fluid resuscitation — target urine output ~200–300 mL/hr for rhabdomyolysis management [1]
- Cooling — acetaminophen 1000 mg q6h, evaporative cooling (mists + fans), surface thermoregulation devices [1]
Pharmacologic treatment (tiered approach)
- Mild rigidity: lorazepam for muscle relaxation [1]
- Moderate-severe rigidity (temp 38–40°C, sustained rigidity): [1]
- Dantrolene 1–2.5 mg/kg IV, may repeat q6–12h; monitor LFTs for hepatotoxicity
- Bromocriptine 2.5 mg PO/NG q8h, titrate up to 45 mg/day
- Amantadine 100 mg PO/NG q8h as alternative
- Refractory/life-threatening cases: ECT has been reported rapidly effective [1]
Supportive ICU care
- Dexmedetomidine for agitation/sedation (avoids reintroducing antipsychotics) [1]
- Glycopyrrolate for sialorrhea [1]
- Correct electrolyte derangements: hypocalcemia, hypomagnesemia, hyperkalemia [1]
- Clonidine or calcium-channel blockers (clevidipine, nicardipine) for severe BP instability [1]
- DVT prophylaxis, stress ulcer prophylaxis if ventilated [1]
- Consider dialysis for severe hyperkalemia, azotemia, or volume overload [1]
17. Disposition
- All confirmed or suspected NMS requires admission — most patients need ICU-level care [1][7]
- 45% of patients in one series required mechanical ventilation [7]
- Admission criteria: any combination of fever + rigidity + AMS in the setting of dopamine-blocker exposure
- Observation/step-down: mild cases with low-grade fever, mild rigidity, stable vitals, and normal CK may be monitored on a telemetry floor with frequent reassessment
- Consult: psychiatry (medication management, rechallenge planning), neurology (if diagnostic uncertainty), nephrology (if AKI), critical care
18. Follow Up / Return Precautions
Recovery course
- Mean recovery time 7–10 days after drug discontinuation for oral agents; prolonged with long-acting injectables [1-2]
- Recovery with dantrolene averages ~9 days; with bromocriptine ~10 days; supportive care alone ~15 days [1]
Rechallenge considerations
- Wait ≥2 weeks after complete resolution of all NMS features before considering antipsychotic rechallenge [1][11]
- Use a low-potency or atypical agent different from the causative drug, at the lowest dose with slow titration [1]
- Recurrence risk exists but is relatively low; reported even up to 2 years after first episode [1]
Patient/family counseling
- Educate about NMS risk with future antipsychotic use [11]
- Ensure close psychiatric follow-up for alternative medication planning
- Return immediately for fever, muscle stiffness, confusion, dark urine, or difficulty breathing after any future antipsychotic exposure
- Ensure adequate hydration and avoid dehydration with any future antipsychotic use
References
1. Neuroleptic Malignant Syndrome. — Wijdicks EFM, Ropper AH. The New England Journal of Medicine. 2024.
2. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
3. Hyperthermia. — Simon HB. The New England Journal of Medicine. 1993.
4. Case Report: Atypical Neuroleptic Malignant Syndrome Induced by Paliperidone Palmitate-Diagnostic Challenges and Clinical Considerations. — El Oumary O, Laaraj H, Ouhamou M, et al. Frontiers in Psychiatry. 2025.
5. Clinical and Pharmacologic Risk Factors for Neuroleptic Malignant Syndrome: A Case-Control Study. — Berardi D, Amore M, Keck PE, Troia M, Dell'Atti M. Biological Psychiatry. 1998.
6. Neuroleptic Malignant Syndrome: An Easily Overlooked Neurologic Emergency. — Oruch R, Pryme IF, Engelsen BA, Lund A. Neuropsychiatric Disease and Treatment. 2017.
7. Contemporary Perspectives in Critical Care of Neuroleptic Malignant Syndrome. — Lopez O, Rabinstein AA, Wijdicks EFM. Neurocritical Care. 2025.
8. Resource Document on Catatonia. — Jo Ellen Wilson, Mark A. Oldham, Andrew Francis, et al American Psychiatric Association (2025). 2025.
9. Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture. — Factor SA, Burkhard PR, Caroff S, et al. The Lancet. Neurology. 2019.
10. An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi Method. — Gurrera RJ, Caroff SN, Cohen A, et al. The Journal of Clinical Psychiatry. 2011.
11. Neuroleptic Malignant Syndrome. Recognition, Prevention and Management. — Velamoor VR. Drug Safety. 1998.